Mizuho Upgrades Outlook: Harmony’s Wakix Now Protected Until 2030
Harmony Biosciences wins key patent lawsuit, protecting Wakix from generics until ~2030; analyst stays positive with $50 target.
Harmony Biosciences wins key patent lawsuit, protecting Wakix from generics until ~2030; analyst stays positive with $50 target.
BTIG raises CMPS to Buy, $14 target; stock jumps 42% after Trump boosts psychedelic research funding and faster FDA paths.
Achieve Life Sciences gets Buy rating as its quit-smoking drug cytisinicline shows strong results; FDA decision due June 2026.
Cantor is very bullish on CADL, sees big undervaluation and CAN-2409 as a major drug with huge growth potential.
Barclays cut Janux Therapeutics to Underweight, citing doubts on JANX007 and limited near-term upside despite long-term potential.
Barclays boosts Celldex Therapeutics on strong drug outlook; higher success odds and sales expectations.